Search Results - "HOETELMANS, Richard"
-
1
Infliximab Concentrations in Participants with Moderate to Severe COVID‐19
Published in Journal of clinical pharmacology (01-04-2024)Get full text
Journal Article -
2
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine
Published in Clinical pharmacokinetics (01-01-2009)“…Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. It has a high genetic…”
Get full text
Journal Article -
3
Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs
Published in Clinical pharmacokinetics (2011)“…Etravirine (formerly TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against wild-type and NNRTI-resistant strains of HIV-1…”
Get full text
Journal Article -
4
Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates
Published in The Journal of pharmacology and experimental therapeutics (01-10-2023)“…Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biological drivers in antibody production…”
Get full text
Journal Article -
5
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers
Published in Journal of clinical pharmacology (01-08-2014)“…This study compared the bioavailability of two candidate fixed‐dose combinations (FDCs: G003 and G004) of darunavir/cobicistat 800/150 mg with that of…”
Get full text
Journal Article -
6
Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
Published in Clinical pharmacology and therapeutics (01-02-2023)“…Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID‐19) is critical for informing the…”
Get full text
Journal Article -
7
Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine
Published in Journal of clinical pharmacology (01-08-2013)“…The objective of the study was to determine the impact of food and different meal types on the pharmacokinetics of rilpivirine, a nonnucleoside reverse…”
Get full text
Journal Article -
8
Single‐ and multiple‐dose pharmacokinetics and safety of pimodivir, a novel, non‐nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open‐label study in healthy volunteers
Published in British journal of clinical pharmacology (01-11-2018)“…Aims The aim of this study was to evaluate the drug–drug interaction between pimodivir, a novel, non‐nucleoside polymerase basic protein 2 (PB2) subunit…”
Get full text
Journal Article -
9
The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers
Published in Journal of clinical pharmacology (01-04-2007)“…This open‐label, randomized, crossover study investigated the bioavailability, short‐term safety, and tolerability of darunavir (TMC114) coadministered with…”
Get full text
Journal Article -
10
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir
Published in Journal of antimicrobial chemotherapy (01-10-2014)“…The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic regimens required for the successful treatment of HIV infection…”
Get full text
Journal Article -
11
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects
Published in Journal of clinical pharmacology (01-04-2014)“…The effect of etravirine on cytochrome P450 (CYP) enzymes and P‐glycoprotein were evaluated in two randomized, crossover trials in healthy subjects. A modified…”
Get full text
Journal Article -
12
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
Published in Antimicrobial Agents and Chemotherapy (01-12-2008)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
13
Darunavir : pharmacokinetics and drug interactions
Published in Antiviral therapy (2008)“…Darunavir (TMC114) is a new HIV protease inhibitor that has demonstrated substantial antiretroviral activity against wild-type HIV-1 virus and…”
Get full text
Journal Article -
14
Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers
Published in Antiviral therapy (01-01-2014)“…Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir…”
Get more information
Journal Article -
15
Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials
Published in Antimicrobial Agents and Chemotherapy (01-05-2011)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
16
Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment
Published in Clinical pharmacokinetics (01-05-2010)“…Background and Objective The pharmacokinetics of some HIV protease inhibitors are altered in patients with hepatic impairment. The TMC114-C134 study assessed…”
Get full text
Journal Article -
17
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial
Published in Journal of clinical pharmacology (01-05-2014)“…Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non‐nucleoside reverse transcriptase…”
Get full text
Journal Article -
18
The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers
Published in Journal of clinical pharmacology (01-02-2014)“…Antiretrovirals may influence methadone exposure in HIV‐1‐infected patients receiving methadone for opiate addiction. Rilpivirine is a non‐nucleoside reverse…”
Get full text
Journal Article -
19
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies
Published in Journal of antimicrobial chemotherapy (01-03-2014)“…Drug-drug interactions between etravirine and rifabutin or clarithromycin were examined in two separate open-label, randomized, two-period, crossover trials in…”
Get full text
Journal Article -
20
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers
Published in British journal of clinical pharmacology (01-11-2007)“…What is already known about this subject • Tenofovir disoproxil fumarate and some of the HIV protease inhibitors show drug–drug interactions that cannot be…”
Get full text
Journal Article